OpenEvidence, which is building “ChatGPT for doctors”, raised $250M led by Thrive and DST at a $12B valuation, up from $6B in October and $1B in February 2025
Context & Ripple Effects
OpenEvidence’s financing trajectory has accelerated from its first outside round at a $1B valuation in February 2025 to a $6B valuation in October. The intervening coverage characterized its physician chatbot as ad-supported, making the valuation rise relevant not only to clinical-AI adoption but also to the durability of its commercial model.
A December report had already described a proposed $12B round and $150M in annualized ad revenue; this financing turns that reported fundraise and revenue milestone into a clearer market signal. OpenEvidence also says its medical search service reaches a large share of U.S. physicians, giving the raise relevance for companies seeking clinician attention.
First-order effects
- OpenEvidence gains $250M of additional capital and a valuation benchmark of $12B, strengthening its ability to invest in its medical-search product and physician distribution.
- Thrive and DST become more financially exposed to OpenEvidence’s ability to sustain growth in a clinician-facing, advertising-supported service.
Second-order effects
- Rival clinical-AI and medical-information products face greater pressure to demonstrate both physician usage and a credible route to monetization, rather than relying on general AI interest alone.
- The company’s scale makes access to clinicians a more valuable channel for advertisers and healthcare-industry customers, while increasing the importance of maintaining trust in a commercial medical-search setting.
Third-order effects
- If high valuations continue to follow physician adoption and monetization, clinical AI may concentrate around a smaller set of platforms that can combine trusted workflows, distribution, and commercial demand.
- The model’s expansion could sharpen scrutiny of how advertising and other business incentives are separated from medical information; that outcome depends on how usage and revenue hold up after the financing.
The trend: This is a data point in the shift from broad healthcare-AI experimentation toward heavily funded clinician-facing platforms expected to prove repeatable distribution and monetization.